A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
Key facts
- Where
- Amberg, Bad Mergentheim, Bad Reichenhall, Berlin, Bünde, Daaden, Dortmund, Dresden, Duisburg, Eisenach, Essen, Fulda, Hamburg, Hof, Jerichow, Leipzig, Lichtenfels, Ludwigsburg, Osnabrück, Pohlheim, Singen (Hohentwiel), and Trier, GermanySee the 23 sites
- Phase
- Phase 4
Where in Germany
- Versdias GmbHAmberg, GermanyNot yet recruiting
- MVZ DiaMedicum Bad Mergentheim GmbHBad Mergentheim, GermanyNot yet recruiting
- Praxis Dr. Stephan ScharlaBad Reichenhall, GermanyNot yet recruiting
- Medizinisches Versorgungszentrum Am Bahnhof Spandau GbRBerlin, GermanyNot yet recruiting
- Studiengesellschaft Drs Könemann / SteinmannBünde, GermanyNot yet recruiting
- Diabetologische Schwerpunktpraxis DaadenDaaden, GermanyNot yet recruiting
- Diabeteszentrum-Do Dres. K U. Ch. Busch GbRDortmund, GermanyNot yet recruiting
- Studienzentrum Dr. Faulmann GbRDresden, GermanyNot yet recruiting
- MVZ Hausärzte Großenbaum GmbHDuisburg, GermanyNot yet recruiting
- Praxis für Diabetologie, Angiologie und Innere Medizin EisenachEisenach, GermanyNot yet recruiting
- MVZ Contilia GmbH - Studienzentrum DiabetologieEssen, GermanyNot yet recruiting
- Praxis am Markt Dr. BeckerEssen, GermanyNot yet recruiting
- MVZ im Altstadt-Carree Fulda GmbHFulda, GermanyNot yet recruiting
- Diabetes Zentrum Wilhelmsburg GbRHamburg, GermanyNot yet recruiting
- Mesut Durmaz Schwerpunktpraxis für Diabetes, Hormone & Stoffwechsel StudienzentrumHof, GermanyNot yet recruiting
- Praxisgemeinschaft Jerichow SchulzeJerichow, GermanyNot yet recruiting
- Familienmedizinisches Zentrum RadowskyLeipzig, GermanyNot yet recruiting
- Praxis Am Oberen TorLichtenfels, GermanyNot yet recruiting
- Diabeteszentrum LudwigsburgLudwigsburg, GermanyNot yet recruiting
- Institut für Diabetesforschung OsnabrückOsnabrück, GermanyNot yet recruiting
- Centrum Fuer Diabetologie Und AllgemeinmedizinPohlheim, GermanyNot yet recruiting
- Gesundheitsverbund Landkreis Konstanz gGmbHSingen (Hohentwiel), GermanyNot yet recruiting
- Praxis Dr. Astrid Schmidt-ReinwaldTrier, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07112339EU 2024-520068-32-00
- Record updated
- 11 August 2026
- Original description
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.Read full original descriptionShow less
EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.
Inclusion: Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening; Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening:; Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist; Need of intensification with basal insulin, as indicated at the discretion of the investigator; Recorded HbA1c value ≥7% within the last 90 days prior to randomization.
Exclusion: Previous participation in this study. Participation is defined as signed informed consent; Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening; Known or suspected hypersensitivity to study intervention(s) or related products; Any disorder which in the investigator's opinion might jeopardize participant's safety; Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method.